Gilead Sciences, Inc. (NASDAQ:GILD) most recently reported quarterly actual earnings per share of $3.03 for the period ending on 2016-06-30. Prior to the company reporting, consensus estimates based on data from Zacks Research projected the company to report EPS of $3.02. The difference between the estimate and the actual EPS was $0.01 creating a surprise factor of 0.33%. Currently, the company has an impact score of 85. The likelihood that the stock will move on news is greater with a higher impact score. According to Beta Research, the stock has a sentiment score of 0.273. On a scale between 1 and -1, a positive score tends to portray a favorable view of company results by news outlets. The opposite is true for a negative sentiment score.

In taking a look at where the stock might be headed, analysts have a consensus price target of $109 on the shares. The most bullish brokerage firm has a $122 target, while the most bearish sees the stock headed towards $91. This is according to the 13 estimates taken into consideration by Zacks Research.

In terms of Buy/Sell recommendations, analysts have a consensus rating of 1.89. This is according to a simplified scale where 1 represents a Strong Buy and 5 a Strong Sell recommendation. There were 13 recommendations taking into account in order to arrive at this number. Of the 13, 10 have a Strong Buy rating and 1 are rating it a Buy.

Gilead Sciences, Inc. (Gilead) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Gilead’s primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases, such as hepatitis B and C and cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Asia Pacific. The Company’s products include Atripla, Truvada, Viread, Complera/Eviplera, Emtriva, Hepsera, Letairis, Ranexa, Lexiscan/Rapiscan, AmBisome, Vistide, Macugen, Cayston and Tamiflu. In January 2012, the Company acquired Pharmasset, Inc. On February 8, 2013, its subsidiary, acquired YM BioSciences Inc.

Gilead Sciences, Inc. - Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with’s FREE daily email newsletter.